A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer

PURPOSE: Preclinical tumor models show that chemotherapy has immune modulatory properties which can be exploited in the context of immunotherapy. The purpose of this study was to determine the feasibility and immunogenicity of combinations of such an immunomodulatory chemotherapeutic agent with immu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Dijkgraaf, Eveline M., Santegoets, Saskia J.A.M., Reyners, An K.L., Goedemans, Renske, Nijman, Hans W., van Poelgeest, Mariëtte I.E., van Erkel, Arien R., Smit, Vincent T.H.B.M., Daemen, Toos A.H.H., van der Hoeven, Jacobus J.M., Melief, Cornelis J.M., Welters, Marij J.P., Kroep, Judith R., van der Burg, Sjoerd H.
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2015
Assuntos:
Clinical Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4741673/
https://ncbi.nlm.nih.gov/pubmed/26334096
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados